MX2023014437A - Compuestos de triptamina fluorada, análogos de estos y métodos de uso estos. - Google Patents
Compuestos de triptamina fluorada, análogos de estos y métodos de uso estos.Info
- Publication number
- MX2023014437A MX2023014437A MX2023014437A MX2023014437A MX2023014437A MX 2023014437 A MX2023014437 A MX 2023014437A MX 2023014437 A MX2023014437 A MX 2023014437A MX 2023014437 A MX2023014437 A MX 2023014437A MX 2023014437 A MX2023014437 A MX 2023014437A
- Authority
- MX
- Mexico
- Prior art keywords
- fluorinated
- analogues
- methods
- same
- tryptamine compounds
- Prior art date
Links
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical class C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 title abstract 2
- 208000020016 psychiatric disease Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195943P | 2021-06-02 | 2021-06-02 | |
| US202163288313P | 2021-12-10 | 2021-12-10 | |
| PCT/US2022/032000 WO2022256554A1 (en) | 2021-06-02 | 2022-06-02 | Fluorinated tryptamine compounds, analogues thereof, and methods using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014437A true MX2023014437A (es) | 2024-03-08 |
Family
ID=84324579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014437A MX2023014437A (es) | 2021-06-02 | 2022-06-02 | Compuestos de triptamina fluorada, análogos de estos y métodos de uso estos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240286998A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4347559A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024523822A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240017363A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022287013A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023025340A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3220850A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2023018652A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308944A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014437A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022256554A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023002557A (es) * | 2020-09-01 | 2023-05-29 | Enveric Biosciences Canada Inc | Derivados de psilocibina halogenada y metodos de uso. |
| EP4396162A4 (en) | 2021-09-03 | 2025-11-12 | Alexander Shulgin Res Institute Inc | ASYMMETRIC ALLYL TRYPTAMINES |
| WO2023147424A1 (en) * | 2022-01-27 | 2023-08-03 | Terran Biosciences, Inc. | Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine |
| US12157722B1 (en) * | 2023-08-03 | 2024-12-03 | Gilgamesh Pharmaceuticals, Inc. | Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| US12129234B1 (en) | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| CN121866243A (zh) * | 2023-09-07 | 2026-04-14 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 致幻化合物、其制备方法及其用途 |
| WO2025104491A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0848706B1 (en) * | 1995-06-06 | 2003-02-05 | Schering Corporation | Substituted benzene-fused heterocyclics as neurokinin antagonists |
| DE19615232A1 (de) * | 1996-04-18 | 1997-10-23 | Merck Patent Gmbh | Neue Carbamoylderivate und deren Verwendung als 5-HT ¶1¶¶A¶-Antagonisten |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| AR021509A1 (es) * | 1998-12-08 | 2002-07-24 | Lundbeck & Co As H | Derivados de benzofurano, su preparacion y uso |
| US6800637B2 (en) * | 2002-09-12 | 2004-10-05 | Wyeth | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines |
| JP7273731B2 (ja) * | 2017-02-09 | 2023-05-15 | カームテック、エルエルシー | シロシビン誘導体を含む組成物及び方法 |
| WO2019222552A1 (en) * | 2018-05-16 | 2019-11-21 | University Of Florida Research Foundation | Methods and compositions for substituted 2,5-diketopiperazine analogs |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| AU2021215709A1 (en) * | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| LT4084791T (lt) * | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| MX2023002557A (es) * | 2020-09-01 | 2023-05-29 | Enveric Biosciences Canada Inc | Derivados de psilocibina halogenada y metodos de uso. |
| CA3192617A1 (en) * | 2020-09-20 | 2022-03-24 | Matthew BAGGOTT | Advantageous tryptamine compositions for mental disorders or enhancement |
| US20240051978A1 (en) * | 2020-12-07 | 2024-02-15 | Mindset Pharma Inc. | 3-cyclic amine-indole derivatives as serotonergic agents for the treatment of cns disorders |
-
2022
- 2022-06-02 KR KR1020237044652A patent/KR20240017363A/ko active Pending
- 2022-06-02 MX MX2023014437A patent/MX2023014437A/es unknown
- 2022-06-02 CA CA3220850A patent/CA3220850A1/en active Pending
- 2022-06-02 AU AU2022287013A patent/AU2022287013A1/en active Pending
- 2022-06-02 EP EP22816868.8A patent/EP4347559A4/en active Pending
- 2022-06-02 IL IL308944A patent/IL308944A/en unknown
- 2022-06-02 US US18/565,565 patent/US20240286998A1/en active Pending
- 2022-06-02 WO PCT/US2022/032000 patent/WO2022256554A1/en not_active Ceased
- 2022-06-02 JP JP2023574858A patent/JP2024523822A/ja active Pending
- 2022-06-02 BR BR112023025340A patent/BR112023025340A2/pt unknown
-
2023
- 2023-12-29 CO CONC2023/0018652A patent/CO2023018652A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL308944A (en) | 2024-01-01 |
| JP2024523822A (ja) | 2024-07-02 |
| CO2023018652A2 (es) | 2024-01-25 |
| US20240286998A1 (en) | 2024-08-29 |
| EP4347559A1 (en) | 2024-04-10 |
| CA3220850A1 (en) | 2022-12-08 |
| EP4347559A4 (en) | 2025-04-09 |
| AU2022287013A1 (en) | 2023-12-07 |
| KR20240017363A (ko) | 2024-02-07 |
| WO2022256554A1 (en) | 2022-12-08 |
| BR112023025340A2 (pt) | 2024-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023018652A2 (es) | Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estos | |
| CL2020002034A1 (es) | Agonista triple de receptores de glucagón/glp-1/gip. (divisional solicitud 201801776) | |
| CL2019003800A1 (es) | Métodos para tratar la enfermedad de huntington. | |
| CO2020001220A2 (es) | Compuestos, composiciones y métodos | |
| CL2019002574A1 (es) | Moduladores de la expresión de pcsk9. | |
| MX2022005380A (es) | Composiciones que comprenden colina. | |
| ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
| CO2021008816A2 (es) | Moduladores de trex1 | |
| CU24743B1 (es) | Composiciones inmunogénicas contra el coronavirus | |
| MX2016011063A (es) | Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica. | |
| MX2018000412A (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2). | |
| CL2020002841A1 (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| MX2022003689A (es) | Metodos y composiciones para el tratamiento contra una enfermedad o trastorno. | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| MX2020013004A (es) | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. | |
| UY38969A (es) | Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos | |
| AR090642A1 (es) | Metodo para elaborar una composicion con sales de aluminio | |
| MX2017011500A (es) | Combinaciones y formulaciones de dosis fijas que comprenden ácido 8-hidroxi-2,2,14,14- tetrametilpentadecanodioico (etc1002) y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| CL2025003977A1 (es) | Nuevos totivirus piscícolas. | |
| SV2018005701A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| MX2022005354A (es) | Uso de un inhibidor de la cinasa janus y un inhibidor de la telomerasa para el tratamiento de neoplasias mieloproliferativas. | |
| MX2022000356A (es) | Compuesto para tratamiento de combinacion. | |
| CL2017000302A1 (es) | Composición semioquímica inhibidora de la fijacion de copepoditos de piojos de mar | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac |